Weekly Top Stories: First Bilingual MAiD Curriculum, New Funding for Distress and Crisis Centres, $3.4M for Biomed Research

Published on
September 18, 2023
Written by
Delphic Research
Read time
3 min

In Canada's evolving life sciences sector this week, significant developments are reshaping healthcare. Highlights include new fund allocations, reforms, and efforts to address drug restrictions, all of which collectively influence the trajectory of healthcare quality and accessibility throughout Canada. 

The Canadian government has introduced the first accredited bilingual Medical Assistance in Dying (MAiD) Curriculum for physicians and nurse practitioners. This curriculum aims to ensure consistent and safe care for MAiD requests, including those from individuals with mental illness, chronic conditions, and structural vulnerability, while also preparing for the end of the MAiD eligibility exclusion for mental illness, set to take effect in March 2024. 

Meanwhile, in the field of organ transplantation, the federal administration has taken on the role of a driving force for change. The tireless efforts to enhance access to living donor kidney transplantation (LDKT) for minority communities have borne fruit. These efforts, underpinned by culturally sensitive educational resources and sustained engagement with diverse ethnic groups, have yielded an impressive 20% surge in living donor rates during 2021. This resurgence follows a period of declining organ donation and transplantation rates during the pandemic, bringing renewed hope to numerous patients. 

In anticipation of World Suicide Prevention Day, Minister of Mental Health and Addictions Ya'ara Saks, announced an $8 million federal funding initiative. This initiative is designed to enhance equity in distress and crisis centers, complementing the upcoming launch of the 9-8-8: Suicide Crisis Helpline, which aims to ensure equitable access to crisis services for all Canadians. 

Yet amidst these laudable strides, Health Canada urges vigilance as unauthorized health products continue to spread. The agency has issued alerts regarding unauthorized sexual enhancement products, skin lightening products, and workout supplements, citing potential risks associated with these products, including the presence of prescription drugs and unapproved ingredients. Notably, sexual enhancement products like "Black Panther Super 500K," "Magnum XXL 500K," and "Magnum XXL 9800" have been found to contain prescription drugs like levodopa and controlled substances like prasterone. Health Canada strongly advises against their use, emphasizing the importance of obtaining prescription drugs exclusively from licensed pharmacies. 

Health Canada has also issued a public advisory concerning nine unauthorized health products seized from a store in British Columbia. These products are misleadingly labeled to contain prescription, controlled, or over-the-counter drugs. Alarmingly, two of these products, Mentholatum Mediquick Eczema Rash Anti-Itch Cream and Mentholatum Mediquick Ointment, marketed for eczema and rash relief, have been unmasked as carriers of prednisolone valerate acetate, a prescription corticosteroid unauthorized for use in creams or ointments in Canada. 

Meanwhile, the Canadian Agency for Drugs and Technologies in Health (CADTH) has recommended reimbursement for AbbVie's Vyalev (foslevodopa foscarbidopa) for the treatment of motor fluctuations in advanced levodopa-responsive Parkinson's disease, under specific conditions. These conditions include limiting reimbursement to patients with severe limitations in daily activities due to unpredictable movement symptom changes. It also requires prescriptions from specialized neurologists. 

CADTH has also conditionally recommended reimbursement for abiraterone acetate in combination with prednisolone for high-risk non-metastatic prostate cancer patients beginning long-term androgen deprivation therapy, with specific criteria to be met.  

Institut de recherches cliniques de Montréal (IRCM) continues its commitment to innovation with a record $3.4 million donation from the IRCM Foundation. Of this donation, $2.7 million is allocated to its four main research centers focused on cardiometabolic health, genetic and neurological diseases, cancer, and inflammation. The foundation will also dedicate $412,000 to its student research scholarship program, $96,000 to upgrading the institute's technological capabilities with state-of-the-art equipment, and $150,000 to maintaining IRCM's infrastructure. 

These recent developments in Canada's healthcare sector underscore significant changes and challenges, emphasizing the ongoing importance of vigilance, innovation, and equitable access to quality care. 

Fuel your strategic insights daily. Join us at Delphic Research to explore these narratives further or schedule a consultation to dive deeper into these updates and remain well-informed about the most recent developments shaping the landscape. Book a consultation now! 

Subscribe to our newsletter

Thanks for joining our newsletter
Oops! Something went wrong while submitting the form.